Company profile
Drishti Discoveries LTD.
Drishti Discoveries
Drishti Discoveries LTD. is a UK company with status active founded in 2019 based in East of England.
Latest accounts
Financial period: 1 Apr 2024 to 31 Mar 2025
Company events
Reference milestones and recent Companies House filing stream events.
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts due
Accounts DueNext accounts due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Accounts With Accounts Type Total Exemption Full
Accounts AnalysedAA | Transaction MzQzNzc3Mjg2OGFkaXF6a2N4
Published 30 Sep 2024 03:10
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Development of a Novel Gene Therapy for Neurodegenerative Diseases
1 Oct 2023 to 31 Dec 2024
Amyotrophic Lateral Sclerosis (ALS) is a fatal motor neuron disease that causes death in patients within 3-5 years of diagnosis. Riluzole is the only approved drug in the UK that extends survival by 6 months. Increasing research in the pathophysiology of ALS has led to a deeper understanding of molecular mechanisms underlying the disease progression. Rece...
Multitarget gene therapy for Neurodegenerative Diseases
1 Dec 2022 to 29 Feb 2024
Amyotrophic Lateral Sclerosis (ALS) is a fatal motor neuron disease that causes death in patients within 3-5 years of diagnosis. Riluzole is the only approved drug in the UK that extends survival by 6 months. Increasing research in the pathophysiology of ALS has led to a deeper understanding of molecular mechanisms underlying the disease progression. Rece...
In-vivo gene therapy for Retinitis Pigmentosa
1 Nov 2022 to 30 Apr 2023
Retinitis Pigmentosa (RP) is one of the leading causes of blindness worldwide. RP is a highly heterogeneous disease caused by mutations in one of over 60 genes. Due to the genetic nature of the disease, in-vivo gene therapy is considered to be the most promising approach to treating RP. However, the challenge of developing gene therapies for RP is that ma...